EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSPCTG00005018367
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSPCTG00005004934
Gene Symbol: CACNA1H
1 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSPCTG00005009256
Gene Symbol: CACNA1I
1 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSPCTG00005012697
Gene Symbol: CACNA1S
3 Cross references
259 Possible Orthologues:

Carbonic Anhydrase 5a

Ensembl ID : ENSPCTG00005005310
Gene Symbol: CA5A
1 Cross references
167 Possible Orthologues:

Carbonic Anhydrase 9

Ensembl ID : ENSPCTG00005019627
Gene Symbol: CA9
3 Cross references
280 Possible Orthologues:

Casein Kinase 1 Epsilon

Ensembl ID : ENSPCTG00005021202
Gene Symbol: CSNK1E
2 Cross references
268 Possible Orthologues:

Caspase 1

Ensembl ID : ENSPCTG00005006753
Gene Symbol: CASP1
3 Cross references
451 Possible Orthologues:

Caspase 9

Ensembl ID : ENSPCTG00005021414
Gene Symbol: CASP9
3 Cross references
202 Possible Orthologues:

Cathepsin S

Ensembl ID : ENSPCTG00005009137
Gene Symbol: CTSS
1 Cross references
269 Possible Orthologues:

Cell Division Cycle 7

Ensembl ID : ENSPCTG00005003524
Gene Symbol: CDC7
3 Cross references
208 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSPCTG00005009612
Gene Symbol: CCKAR
3 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).